Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence

Experimental Cell Research

Volumn 316, Issue 2, 2010, Pages 258-271

  Byrne, Ann ^a   McLaren, Rajashree P ^a   Mason, Paul ^a   Chai, Lilly ^a   Dufault, Michael R ^a   Huang, Yinyin ^a   Liang, Beirong ^a   Gans, Joseph D ^a   Zhang, Mindy ^a   Carter, Kara ^a   Gladysheva, Tatiana B ^a   Teicher, Beverly A ^a   Biemann, Hans Peter N ^a   Booker, Michael ^a   Goldberg, Mark A ^a   Klinger, Katherine W ^a   Lillie, James ^a   Madden, Stephen L ^a   Jiang, Yide ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Cell arrest; p21 Cip1; p27 Kip1; pRb; Proteasome; PSMB5; PSMD14; Senescence; siRNA

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEUBIQUITINASE; PROTEASOME; PROTEINASE; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL AGING; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SUBUNIT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION;

EID: 70450233376     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.08.018     Document Type: Article

References (43)

1. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
2. Pickart C.M. Back to the future with ubiquitin. Cell 116 (2004) 181-190
3. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 (2004) 417-421
4. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
5. Yao T., and Cohen R.E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419 (2002) 403-407
6. Verma R., Aravind L., Oania R., McDonald W.H., Yates III J.R., Koonin E.V., and Deshaies R.J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298 (2002) 611-615
7. Glickman M.H., and Adir N. The proteasome and the delicate balance between destruction and rescue. PLoS Biol. 2 (2004) E13
8. Lam Y.A., Xu W., DeMartino G.N., and Cohen R.E. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature 385 (1997) 737-740
9. Spataro V., Toda T., Craig R., Seeger M., Dubiel W., Harris A.L., and Norbury C. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit. J. Biol. Chem. 272 (1997) 30470-30475
10. Rinaldi T., Ricci C., Porro D., Bolotin-Fukuhara M., and Frontali L. A mutation in a novel yeast proteasomal gene, RPN11/MPR1, produces a cell cycle arrest, overreplication of nuclear and mitochondrial DNA, and an altered mitochondrial morphology. Mol. Biol. Cell 9 (1998) 2917-2931
11. Gallery M., Blank J.L., Lin Y., Gutierrez J.A., Pulido J.C., Rappoli D., Badola S., Rolfe M., and Macbeth K.J. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol. Cancer Ther. 6 (2007) 262-268
12. Koulich E., Li X., and Demartino G.N. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol. Biol. Cell 19 (2008) 1072-1082
13. Lundgren J., Masson P., Realini C.A., and Young P. Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13. Mol. Cell. Biol 23 (2003) 5320-5330
14. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., Peacocke M., and Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9363-9367
15. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8 (2008) 512-522
16. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120 (2005) 513-522
17. Collado M., and Serrano M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 6 (2006) 472-476
18. Zhang H.G., Wang J., Yang X., Hsu H.C., and Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23 (2004) 2009-2015
19. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., and Elliott P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 46 (2000) 673-683
20. Ling Y.H., Liebes L., Jiang J.D., Holland J.F., Elliott P.J., Adams J., Muggia F.M., and Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9 (2003) 1145-1154
21. Tsvetkov L.M., Yeh K.H., Lee S.J., Sun H., and Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr. Biol. 9 (1999) 661-664
22. Sutterluty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Muller U., and Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell. Biol. 1 (1999) 207-214
23. Touitou R., Richardson J., Bose S., Nakanishi M., Rivett J., and Allday M.J. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. Embo J. 20 (2001) 2367-2375
24. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., and Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell. 5 (2000) 403-410
25. Gartel A.L., and Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell. Res. 246 (1999) 280-289
26. Deng Y., Chan S.S., and Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat. Rev. Cancer. 8 (2008) 450-458
27. Shimada K., Nakamura M., Matsuyoshi S., Ishida E., and Konishi N. Specific positive and negative effects of FLIP on cell survival in human prostate cancer. Carcinogenesis 27 (2006) 1349-1357
28. Demartino G.N., and Gillette T.G. Proteasomes: machines for all reasons. Cell 129 (2007) 659-662
29. Reed S.H., and Gillette T.G. Nucleotide excision repair and the ubiquitin proteasome pathway-do all roads lead to Rome?. DNA Repair (Amst) 6 (2007) 149-156
30. Collins G.A., and Tansey W.P. The proteasome: a utility tool for transcription?. Curr. Opin. Genet. Dev. 16 (2006) 197-202
31. Kittler R., Pelletier L., Heninger A.K., Slabicki M., Theis M., Miroslaw L., Poser I., Lawo S., Grabner H., Kozak K., Wagner J., Surendranath V., Richter C., Bowen W., Jackson A.L., Habermann B., Hyman A.A., and Buchholz F. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat. Cell. Biol. 9 (2007) 1401-1412
32. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., and Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3 (1997) 231-234
33. Chiarle R., Budel L.M., Skolnik J., Frizzera G., Chilosi M., Corato A., Pizzolo G., Magidson J., Montagnoli A., Pagano M., Maes B., De Wolf-Peeters C., and Inghirami G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95 (2000) 619-626
34. Kudo Y., Takata T., Ogawa I., Kaneda T., Sato S., Takekoshi T., Zhao M., Miyauchi M., and Nikai H. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6 (2000) 916-923
35. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., and Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 (2001) 3071-3076
36. Roninson I.B. Tumor cell senescence in cancer treatment. Cancer Res. 63 (2003) 2705-2715
37. Broude E.V., Swift M.E., Vivo C., Chang B.D., Davis B.M., Kalurupalle S., Blagosklonny M.V., and Roninson I.B. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 26 (2007) 6954-6958
38. Normand G., Hemmati P.G., Verdoodt B., von Haefen C., Wendt J., Guner D., May E., Dorken B., and Daniel P.T. p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. J. Biol. Chem. 280 (2005) 7118-7130
39. Chau B.N., and Wang J.Y. Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3 (2003) 130-138
40. Alexander K., and Hinds P.W. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol. Cell. Biol. 21 (2001) 3616-3631
41. Lu S., Yang J., Song X., Gong S., Zhou H., Guo L., Song N., Bao X., Chen P., and Wang J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 326 (2008) 423-431
42. Lu S., Chen Z., Yang J., Chen L., Gong S., Zhou H., Guo L., and Wang J. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp. Hematol. 16 (2008) 16
43. Oerlemans R., Franke N.E., Assaraf Y.G., Cloos J., van Zantwijk I., Berkers C.R., Scheffer G.L., Debipersad K., Vojtekova K., Lemos C., van der Heijden J.W., Ylstra B., Peters G.J., Kaspers G.L., Dijkmans B.A., Scheper R.J., and Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112 (2008) 2489-2499